IP Library Granted Patent US 8,182,995
Granted Patent B2
US 8,182,995 · App. 12/686,448 · Granted May 22, 2012

Real time gene expression profiling

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,182,995
App. No.
12/686,448
Granted
May 22, 2012
Kind
B2
Abstract

The invention relates to methods of monitoring the amplification of one or more nucleic acid sequences of interest. More particularly, the invention relates to methods of monitoring the amplification of sequences of interest in real time. The methods disclosed herein provide methods for monitoring the amplification of one sequence or two or more sequences from a single sample, as well as methods for monitoring the amplification of one or more than one sequence from two or more samples. The monitoring methods of the invention permit improved determination of the abundance of one or more target nucleic acids, especially target RNA species, in one or more original samples.

Claims (9)

1. A method for monitoring the amplification of a set of nucleic acid sequences of interest, said method comprising:

(a) contacting a nucleic acid sample in a reaction vessel with a set of pairs of oligonucleotide primers, wherein:

each said pair comprises a first oligonucleotide primer that specifically hybridizes with a nucleic acid molecule comprising said nucleic acid sequence of interest, and a second oligonucleotide primer that specifically hybridizes with a sequence comprised by the complement of said nucleic acid sequence of interest, wherein the primer extension product of one oligonucleotide primer, when separated from its complement, can serve as a template for the synthesis of the extension product of the other primer; each said pair of oligonucleotides is specific for one nucleic acid sequence of interest; each oligonucleotide primer pair in said set is selected so that it generates a distinctly sized amplification product in a subsequent amplification regimen; and one oligonucleotide in each said pair of oligonucleotides is detectably labeled;

b) subjecting the mixture resulting from step (a) to an amplification regimen comprising at least two iterative cycles of nucleic acid strand separation, oligonucleotide primer annealing and polymerase extension of annealed primers, wherein during the amplification regimen, following at least one of said iterative cycles, an aliquot of said mixture is removed from said reaction vessel and nucleic acid molecules in said aliquot are separated;

c) for each aliquot removed and subjected to separation of nucleic acid molecules according to step (b), detecting the incorporation of detectable label in a distinctly sized amplification product present in said aliquot;

d) for each distinctly sized amplification product detected in step (c), calculating a cycle number, C t , where the amount of that amplification product crosses a predefined threshold, and correlating the threshold cycle with the amount of a nucleic acid having a sequence of interest in said sample, wherein said method provides an amplification profile and a relative abundance for members of said set of nucleic acid sequences of interest.

2. The method of claim 1 wherein said detectable label comprises a fluorescent dye.

3. The method of claim 1 wherein aliquot removal of step (b) is performed after each cycle in said amplification regimen.

4. The method of claim 1 wherein said separating nucleic acid molecules comprises capillary electrophoresis.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2021
From: MDG MOLECULAR DIAGNOSTICS GROUP GMBH
To: BIOTYPE DIAGNOSTIC GMBH
Reel/Frame 056808/0683 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 053819 FRAME: 0539. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Jul 9, 2021
From: QIAGEN MANSFIELD, INC.
To: MDG MOLECULAR DIAGNOSTICS GROUP GMBH
Reel/Frame 057667/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2020
From: QIAGEN MANSFIELD, INC.
To: MOLECULAR DIAGNOSTICS GROUP GMBH
Reel/Frame 053819/0539 →
CHANGE OF NAME Recorded Sep 18, 2020
From: BIOTYPE INNOVATION GMBH
To: BIOTYPE GMBH
Reel/Frame 053815/0430 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2020
From: BIOTYPE DIAGNOSTIC GMBH
To: BIOTYPE INNOVATION GMBH
Reel/Frame 053815/0099 →
CHANGE OF NAME Recorded Jun 24, 2015
From: PRIMERADX, INC.
To: QIAGEN MANSFIELD, INC.
Reel/Frame 036012/0584 →
CHANGE OF NAME Recorded Nov 5, 2014
From: PRIMERADX, INC.
To: QIAGEN MANSFIELD, INC.
Reel/Frame 034176/0198 →